BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31852801)

  • 1. Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain.
    Wheeler JM; McMillan P; Strovas TJ; Liachko NF; Amlie-Wolf A; Kow RL; Klein RL; Szot P; Robinson L; Guthrie C; Saxton A; Kanaan NM; Raskind M; Peskind E; Trojanowski JQ; Lee VMY; Wang LS; Keene CD; Bird T; Schellenberg GD; Kraemer B
    Sci Transl Med; 2019 Dec; 11(523):. PubMed ID: 31852801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MSUT2 is a determinant of susceptibility to tau neurotoxicity.
    Guthrie CR; Greenup L; Leverenz JB; Kraemer BC
    Hum Mol Genet; 2011 May; 20(10):1989-99. PubMed ID: 21355046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Poly(A) nucleases have differential impact on sut-2 dependent tauopathy phenotypes.
    Kow RL; Strovas TJ; McMillan PJ; Jacobi AM; Behlke MA; Saxton AD; Latimer CS; Keene CD; Kraemer BC
    Neurobiol Dis; 2021 Jan; 147():105148. PubMed ID: 33184027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AlphaScreen Identifies MSUT2 Inhibitors for Tauopathy-Targeting Therapeutic Discovery.
    Baker JD; Uhrich RL; Strovas TJ; Saxton AD; Kraemer BC
    SLAS Discov; 2021 Mar; 26(3):400-409. PubMed ID: 32981422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau-RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change.
    McMillan PJ; Benbow SJ; Uhrich R; Saxton A; Baum M; Strovas T; Wheeler JM; Baker J; Liachko NF; Keene CD; Latimer CS; Kraemer BC
    Brain; 2023 Aug; 146(8):3206-3220. PubMed ID: 36732296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPOP loss of function protects against tauopathy.
    Eck RJ; Kow RL; Black AH; Liachko NF; Kraemer BC
    Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2207250120. PubMed ID: 36574656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Pathological Tau by Small Molecule Inhibition of the Poly(A):MSUT2 RNA-Protein Interaction.
    Baker JD; Uhrich RL; Strovas TJ; Saxton AD; Kraemer BC
    ACS Chem Neurosci; 2020 Aug; 11(15):2277-2285. PubMed ID: 32589834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer's disease.
    McMillan PJ; Strovas TJ; Baum M; Mitchell BK; Eck RJ; Hendricks N; Wheeler JM; Latimer CS; Keene CD; Kraemer BC
    Acta Neuropathol Commun; 2021 Jun; 9(1):117. PubMed ID: 34187600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MSUT2 regulates tau spreading via adenosinergic signaling mediated ASAP1 pathway in neurons.
    Xu H; Qiu Q; Hu P; Hoxha K; Jang E; O'Reilly M; Kim C; He Z; Marotta N; Changolkar L; Zhang B; Wu H; Schellenberg GD; Kraemer B; Luk KC; Lee EB; Trojanowski JQ; Brunden KR; Lee VM
    Acta Neuropathol; 2024 Mar; 147(1):55. PubMed ID: 38472475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of aly/ALYREF suppresses toxicity in both tau and TDP-43 models of neurodegeneration.
    Kow RL; Black AH; Saxton AD; Liachko NF; Kraemer BC
    Geroscience; 2022 Apr; 44(2):747-761. PubMed ID: 35122183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
    Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
    J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezrin Expression is Increased During Disease Progression in a Tauopathy Mouse Model and Alzheimer's Disease.
    Vega IE; Umstead A; Wygant CM; Beck JS; Counts SE
    Curr Alzheimer Res; 2018; 15(12):1086-1095. PubMed ID: 30101710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
    Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies.
    Vanderweyde T; Yu H; Varnum M; Liu-Yesucevitz L; Citro A; Ikezu T; Duff K; Wolozin B
    J Neurosci; 2012 Jun; 32(24):8270-83. PubMed ID: 22699908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential neuroprotective strategies against tauopathy.
    Wheeler JM; Guthrie CR; Kraemer BC
    Biochem Soc Trans; 2012 Aug; 40(4):656-60. PubMed ID: 22817711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy.
    Zhang D; Zhang W; Ming C; Gao X; Yuan H; Lin X; Mao X; Wang C; Guo X; Du Y; Shao L; Yang R; Lin Z; Wu X; Huang TY; Wang Z; Zhang YW; Xu H; Zhao Y
    Neuron; 2024 May; 112(10):1676-1693.e12. PubMed ID: 38513667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy.
    Soler H; Dorca-Arévalo J; González M; Rubio SE; Ávila J; Soriano E; Pascual M
    Neurobiol Aging; 2017 Jan; 49():40-51. PubMed ID: 27743524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
    Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
    Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal loss and inflammation preceding fibrillary tau pathology in a rat model with early human-like tauopathy.
    Emmerson JT; Malcolm JC; Do Carmo S; Nguyen P; Breuillaud L; Martinez-Trujillo JC; Cuello AC
    Neurobiol Dis; 2023 Oct; 187():106317. PubMed ID: 37802153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.